Published 2025-02-01
“…Kwandao Malasai,1,2 Jiraphun Jittikoon,3 Wanvisa Udomsinprasert,3 Pattarawalai Talungchit,4,5 Sitaporn Youngkong,5,6 Sermsiri Sangroongruangsri,6 Surakameth Mahasirimongkol,7 Usa Chaikledkaew5,6 1Social, Economic and Administrative Pharmacy (SEAP) Graduate Program, Faculty of Pharmacy, Mahidol University,
Bangkok, Thailand; 2Social Pharmacy Research Unit, Faculty of Pharmacy, Mahasarakham University, Maha Sarakham, Thailand; 3Department of Biochemistry, Faculty of Pharmacy, Mahidol University,
Bangkok, Thailand; 4Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University,
Bangkok, Thailand; 5Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University,
Bangkok, Thailand; 6Social and Administrative Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy, Mahidol University,
Bangkok, Thailand; 7Information and Communication Technology Center, Office of the Permanent Secretary, Ministry of Public Health, Nonthaburi, ThailandCorrespondence: Usa Chaikledkaew, Social and Administrative Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, 447 Sri-Ayudhaya Road, Rachathewi, Phayathai,
Bangkok, 10400, Thailand, Email usa.chi@mahidol.ac.thPurpose: This study aimed to evaluate the costs and benefits of genetic testing, specifically mutation analysis and prenatal diagnostic testing, for the confirmation of thalassemia in at-risk pregnancies in Thailand, providing crucial insights to inform public health policy decision-making.Patients and Methods: We analyzed the costs and benefits of following standard screening guidelines, which included a sequence of tests such as mean corpuscular volume (MCV)/mean corpuscular hemoglobin (MCH) with dichlorophenol indophenol precipitation (DCIP), hemoglobin (Hb) typing, genetic testing, and amniocentesis. …”
Get full text
Article